Published Studies Related to Mupirocin Topical
A Randomized Controlled Trial Comparing Mupirocin and Polysporin Triple Ointments in Peritoneal Dialysis Patients: The MP3 Study. [2011.12.01]
Background and objectivesInfectious complications remain a significant cause of peritoneal dialysis (PD) technique failure. Topical ointments seem to reduce peritonitis; however, concerns over resistance have led to a quest for alternative agents...
A double-blind, randomized, controlled trial of topical polysporin triple compound versus topical mupirocin for the eradication of colonization with methicillin-resistant Staphylococcus aureus in a complex continuing care population. [2009.09]
BACKGROUND: Intranasal mupirocin or Polysporin Triple (PT) ointment (polymyxin B, bacitracin, gramicidin), in combination with chlorhexidine body washes, have been used for eradicating methicillin-resistant Staphylococcus aureus (MRSA), but no comparative studies have been done... CONCLUSION: Both agents demonstrated poor efficacy and PT was significantly less efficacious than mupirocin at 12 weeks in eradicating MRSA from all sites.
Nasal lavage with mupirocin for the treatment of surgically recalcitrant chronic rhinosinusitis. [2008.09]
OBJECTIVES/HYPOTHESIS: To examine the efficacy and tolerability of topical mupirocin for the management of surgically recalcitrant chronic rhinosinusitis (CRS) associated with Staphylococcus aureus infection. STUDY DESIGN: Prospective open-label pilot study... CONCLUSIONS: Nasal Lavage with 0.05% Mupirocin may represent an effective and well tolerated alternative treatment for postsurgical recalcitrant CRS.
A RANDOMIZED CONTROLLED TRIAL COMPARING MUPIROCIN VERSUS POLYSPORIN TRIPLEa FOR THE PREVENTION OF CATHETER-RELATED INFECTIONS IN PERITONEAL DIALYSIS PATIENTS (THE MP3 STUDY). [2008.01]
BACKGROUND: Peritonitis remains the most serious complication of peritoneal dialysis (PD). Gram-positive organisms are among the most common causes of PD peritonitis; however, recent trends show increasing rates of gram-negative and fungal infections.Discussion: The results of this study will help determine if the use of P3 is superior to mupirocin ointment in the prevention of catheter-related infections and will help guide evidence-based best practices.
Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience. 
INTRODUCTION: The application of mupirocin to the exit-site in peritoneal dialysis (PD) patients decreases peritonitis and exit-site infection (ESI) considerably. However, long-term application of mupirocin may result in the development of methicillin- and mupirocin-resistant strains. In this study, we aimed to investigate the effect of once-a-week vs. thrice-a-week application of mupirocin on mupirocin and methicillin resistance in PD patients... CONCLUSION: The thrice-a-week application of mupirocin seems to be more efficient when compared to once-a-week application of mupirocin. Long-term application of mupirocin may cause the development of mupirocin- and methicillin-resistant strains, especially in CNS, which results in a difficulty for struggling against infections.
Clinical Trials Related to Mupirocin Topical
Topical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis [Not yet recruiting]
Catheter-related infection, namely exit site infection and peritonitis, is the commonest
complication of peritoneal dialysis. This complication causes significant morbidity and
mortality in patients requiring peritoneal dialysis. Topical application of mupirocin 2%
cream was first proven to be effective in reduction of staphylococcus-related catheter
infection in 1990s. Subsequent randomized trial published in 2005 showed that gentamicin
cream was superior to mupirocin 2% cream in reducing both Gram's positive and Gram's
negative related catheter infection. However, a retrospective report published in 2007 puts
the use of prophylactic antibiotic cream into a question. It reported an emergency of
non-tuberculous mycobacterial infection in a dialysis center in Hong Kong after practising
prophylactic application of gentamicin cream at the catheter exit site. The following
prospective, randomized and open-label study aims to find out an optimal regimen of topical
antibiotic prophylaxis in patients requiring peritoneal dialysis.
Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin [Recruiting]
We hypothesize the application of mupirocin or povidone-iodine to the nares is equally
effective in short term Staphylococcus aureus(SA)suppression. Our overall study objective
is to measure the rate of deep and superficial Surgical Site Infections (SSIs) after primary
hip, knee, shoulder and elbow arthroplasty surgery and primary spinal fusion surgery
requiring implantation of prosthetic material, when the patient receives either nasal
mupirocin or nasal povidone-iodine prior to surgery.
Secondary study objectives include:
1. Measure hospital length of stay and re-admission rates in the mupirocin and
2. Measure adverse events related to mupirocin and povidone-iodine.
3. Measure rate of SA resistance to mupirocin.
Nasal Application of 5% Tea Tree Oil (TTO) Versus Mupirocin for the Prevention of Catheter-associated Infections in Renal Dialysis Patients [Recruiting]
This study will compare the use of tea tree oil against mupirocin as a topical nasal
antiseptic to see which is best at preventing infections in patients that need renal
dialysis. Fifty subjects will be recruited into each arm of the trial and will be assessed
for signs of infection once per week for the first 6 weeks and then every 4 weeks until week
26. They will also be checked for nasal carriage of 'Golden Staph' when they enroll in the
trial. The subjects will complete the trial if they have 26 weeks infection-free or if they
have an infection during that period
Randomized Controlled Trial of Standard Versus Systemic Decolonization Therapy for the Eradication of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization [Recruiting]
MRSA decolonization may reduce the risk of subsequent MRSA infection and further
transmission. A recent randomized controlled trial demonstrated that systemic decolonization
may be safe and effective among hospitalized patients when compared to no treatment. As a
large number of the investigators patients require re-admission and further transmission may
take place in the community, the investigators are comparing the standard decolonization
protocol for MRSA eradication to the systemic decolonization protocol among an ambulatory
Standard decolonization protocols, which use only topical agents, are limited in efficacy.
The method of systemic decolonization to be studied here appears to have greater efficacy
than the standard approach using only topical agents. However, concerns have been raised
that the increased use of systemic antibiotics may lead to increased levels of drug
resistance adverse effects, without sustained decolonization. This study seeks to provide
further data to help answer these questions and provide guidance for further policy
development and implementation.
Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) [Recruiting]
The prevalence of methicillin resistant Staphylococcus aureus (MRSA) respiratory infection
in Cystic Fibrosis (CF) has increased dramatically over the last decade. Evidence suggests
that persistent infection with MRSA may result in an increased rate of decline in FEV1 and
shortened survival. Currently there are no conclusive studies demonstrating an effective
aggressive treatment protocol for persistent MRSA respiratory infection in CF. Data
demonstrating an effective and safe method of clearing persistent MRSA infection are needed.
The purpose of this study is to evaluate the safety and efficacy of a 28-day course of
vancomycin for inhalation, 250 mg twice a day, (in combination with oral antibiotics) in
eliminating MRSA from the respiratory tract of individuals with CF and persistent MRSA
infection. Subjects will be assigned in a 1: 1 ratio to either vancomycin for inhalation (250
mg twice a day) or taste matched placebo and will be followed for 3 additional months. In
addition, both groups will receive oral rifampin, a second oral antibiotic (TMP-SMX or
doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes.
Forty patients with persistent respiratory tract MRSA infection will be enrolled in this